Roquefort Therapeutics (LON:ROQ) Trading Down 12.9% – Time to Sell?

Roquefort Therapeutics plc (LON:ROQ)’s stock price was down 12.9% on Tuesday . The company traded as low as GBX 1.40 ($0.02) and last traded at GBX 1.40 ($0.02). Approximately 482,028 shares were traded during mid-day trading, a decline of 80% from the average daily volume of 2,415,301 shares. The stock had previously closed at GBX 1.61 ($0.02).

Roquefort Therapeutics Price Performance

The firm has a market cap of £1.78 million, a PE ratio of -1.16 and a beta of 0.05. The stock has a 50 day simple moving average of GBX 1.68 and a two-hundred day simple moving average of GBX 2.77. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79.

Roquefort Therapeutics (LON:ROQ) last issued its quarterly earnings results on Wednesday, April 30th. The company reported GBX (0.75) (($0.01)) earnings per share for the quarter. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 29.57%.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.